Prothena Corp. Plc PRTA

DUBLIN, Ireland, September 09, 2026--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.

Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DUBLIN, August 06, 2026--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.

DUBLIN, July 30, 2026--Prothena will report its second quarter and first six months of 2026 financial results on August 6, 2026

Over the last 7 days, the United States market has risen by 1.3%, contributing to a robust 28% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business and may align well with current market optimism.

Prothena Corporation plc ( NASDAQ:PRTA ) last week reported its latest quarterly results, which makes it a good time...